Recent Security Class Actions

bluebird bio Inc. Common Stock (NASDAQ: BLUE)

7 Days left to seek lead plaintiff status.

Company Name:bluebird bio Inc. Common Stock
Stock Symbol:NASDAQ: BLUE
Class Period Start:04/24/2023
Class Period End (inclusive):12/08/2023
Filing Deadline:05/27/2024

The Complaint alleges that the Company’s announcement provided investors with false and misleading information in order to bolster investor expectations and share prices. Specifically, the Complaint alleges Defendants created the false impression that: (i) they could obtain FDA approval for lovocel without any box warnings for haematological malignancies; (ii) they would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen their financial position for the lovocel launch; (iii) as a result, the Company had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and (iv) therefore, the Company’s public statements were materially false and misleading at all relevant times, and that as a result, Plaintiff and other shareholders purchased the Company’s securities at artificially inflated prices.

bluebird bio Inc. Common Stock (NASDAQ: BLUE) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.